Malamut Richard 4

What Happened

• Richard Malamut, a director of Pelthos Therapeutics, sold a total of 590 shares of PTHS common stock in open-market transactions on April 2, 2026.
  • 310 shares sold at a weighted average price of $20.51 for proceeds of $6,359.
  • 280 shares sold at a weighted average price of $21.36 for proceeds of $5,981.
• Total proceeds from these sales were approximately $12,340. These were sales (not purchases), and per the filing were made to satisfy tax obligations tied to vested restricted stock units.

Key Details

• Transaction date: 2026-04-02; Form 4 filed: 2026-04-06 (filed within the 2-business-day window, timely).
• Reported prices reflect weighted averages. Individual trade price ranges:
  • 310-share block executed in multiple trades at $20.30–$20.78 (footnote).
  • 280-share block executed in multiple trades at $21.31–$22.03 (footnote).
  • The reporting person offers to provide full trade-by-trade details on request to the SEC, issuer, or a security holder.
• Footnote: Transactions were made under a Rule 10b5-1 trading plan adopted December 16, 2025, specifically to satisfy estimated tax obligations in connection with the vesting of restricted stock units.
• Shares owned after the transaction: not specified in the excerpt provided.

Context

• These sales were executed under a pre-established 10b5-1 plan to cover taxes on vested RSUs, a common, non-speculative reason for insider sales. Sales to cover tax withholding differ from discretionary insider selling and do not by themselves indicate a change in insider confidence. Purchases (when they occur) typically carry more weight as potential bullish signals.